Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLSTICE first-line metastatic colorectal cancer study
2024-516180-85-00Phase 3Authorised
- Sponsor
- Servier
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing Lonsurf + Avastin with Xeloda + Avastin (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2019; status: authorised.
02
Drugs
trifluridine + tipiracilbevacizumabcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-516180-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516180-85-00.